Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does BASILIXIMAB Cause Systemic candida? 20 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 20 reports of Systemic candida have been filed in association with BASILIXIMAB (Simulect). This represents 0.3% of all adverse event reports for BASILIXIMAB.

20
Reports of Systemic candida with BASILIXIMAB
0.3%
of all BASILIXIMAB reports
16
Deaths
17
Hospitalizations

How Dangerous Is Systemic candida From BASILIXIMAB?

Of the 20 reports, 16 (80.0%) resulted in death, 17 (85.0%) required hospitalization, and 2 (10.0%) were considered life-threatening.

Is Systemic candida Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for BASILIXIMAB. However, 20 reports have been filed with the FAERS database.

What Other Side Effects Does BASILIXIMAB Cause?

Cytomegalovirus infection (590) Drug ineffective (567) Off label use (567) Transplant rejection (554) Kidney transplant rejection (456) Product use in unapproved indication (428) Pyrexia (323) Diarrhoea (314) Multiple organ dysfunction syndrome (298) Polyomavirus-associated nephropathy (298)

What Other Drugs Cause Systemic candida?

DEXAMETHASONE (224) CYCLOPHOSPHAMIDE (211) VINCRISTINE (198) PREDNISONE (192) METHYLPREDNISOLONE (187) TACROLIMUS (184) RITUXIMAB (176) CYTARABINE (166) DOXORUBICIN (165) METHOTREXATE (152)

Which BASILIXIMAB Alternatives Have Lower Systemic candida Risk?

BASILIXIMAB vs BAYER GENUINE ASPIRIN ORIGINAL STRENGTH BASILIXIMAB vs BAZEDOXIFENE\ESTROGENS, CONJUGATED BASILIXIMAB vs BCG VACCINE BASILIXIMAB vs BEBTELOVIMAB BASILIXIMAB vs BECLOMETHASONE

Related Pages

BASILIXIMAB Full Profile All Systemic candida Reports All Drugs Causing Systemic candida BASILIXIMAB Demographics